BCL2 and acute myeloid leukemia: FAB5 maturation state in AML is of particular interest because in a recent publication Pei S et al demonstrated that the monocyte morphology was found highly significant to be associated with a disease that was refractory to the combination treatment of hypomethylating agent Azacitidine and the highly specific Bcl-2 inhibitor Venetoclax [81].